General Hospital Psychiatry
Volume 32, Issue 6 , Pages 647.e7-647.e9 , November 2010

Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction

  • Chun-Yen Chen, M.D.

      Affiliations

    • Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    • ,
  • Nian-Sheng Tzeng, M.D.

      Affiliations

    • Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    • ,
  • Yi-Chyan Chen, M.D., Ph.D.

      Affiliations

    • Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
    • Department of Psychiatry, Buddhist Tzu Chi General Hospital, Taipei Branch, Taipei 231, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan. Tel: +886 287923311x12523; fax: +886 2 27956780.

Received 1 April 2010 ,Accepted 6 July 2010.

References 

  1. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–741
  2. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des. 2008;14:1452–1465
  3. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26:607–611
  4. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;
  5. Danese A, Moffitt TE, Pariante CM, et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008;65:409–415
  6. Song C, Zhang XY, Manku M. Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci. 2009;29:14–22
  7. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12:988–1000
  8. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–684
  9. Hu F, Wang X, Pace TW, Wu H, Miller AH. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry. 2005;10:426–428
  10. Guo JY, Li CY, Ruan YP, et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol. 2009;612:54–60
  11. Muller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255:149–151
  12. Qin W, Peng Y, Ksiezak-Reding H, et al. Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease. Mol Psychiatry. 2006;11:172–181
  13. Scali C, Giovannini MG, Prosperi C, et al. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience. 2003;117:909–919
  14. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet. 2007;370:2138–2151
  15. Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf. 2006;29:261–272

PII: S0163-8343(10)00139-8

doi: 10.1016/j.genhosppsych.2010.07.001

General Hospital Psychiatry
Volume 32, Issue 6 , Pages 647.e7-647.e9 , November 2010

Article Tools